专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09040564B2 Stabilized composition 有权
公开(公告)号：US09040564B2
公开(公告)日：2015-05-26
申请号：US11937393
申请日：2007-11-08
申请人： Koji Ukai , Norishige Takami
发明人： Koji Ukai , Norishige Takami
IPC分类号： A61K31/4439 , A61K31/4184 , A61K9/50
CPC分类号： A61K31/4184 , A61K9/5047 , A61K9/5078 , A61K31/4439
摘要： It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the stomach but dissolves in the intestine to release a primary drug product promptly. The object could be achieved by the pharmaceutical composition characterized in that a layer containing a proton pump inhibitor and ethyl cellulose, a layer containing an enteric polymer, and if necessary an intermediate layer composed of one or more layers are formed on a pharmacologically inactive core substance. The intermediate layer is composed of a water-insoluble polymer, a water-soluble polymer, a lubricant and the like.

2. 发明授权

US07727552B1 Oral pharmaceutical preparations decreased in bitterness by masking 失效
标题翻译：口服药物制剂通过掩蔽减少苦味
公开(公告)号：US07727552B1
公开(公告)日：2010-06-01
申请号：US09380310
申请日：1998-03-26
申请人： Koji Ukai , Tsutomu Hrada , Yasuyuki Suzuki
发明人： Koji Ukai , Tsutomu Hrada , Yasuyuki Suzuki
IPC分类号： A61K9/20 , A61K9/34 , A61K9/68 , A61K47/32
CPC分类号： A61K9/0095 , A61K9/1652 , A61K47/36 , Y10S514/974
摘要： A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
摘要翻译：本文公开了可以防止药物令人不快的口服药物或口服药物的组合物。它是防止不愉快味道的颗粒剂，粉末，糖浆等，其包含具有不愉快味道的碱性药物和阴离子聚合物如角叉菜聚糖。

3. 发明申请

US20090274756A1 Stabilized composition 审中-公开
标题翻译：稳定组成
公开(公告)号：US20090274756A1
公开(公告)日：2009-11-05
申请号：US11919229
申请日：2006-04-17
申请人： Koji Ukai , Norishige Takami
发明人： Koji Ukai , Norishige Takami
IPC分类号： A61K9/20 , A61K9/00 , A61K31/435 , A61K9/16 , A61P1/04
CPC分类号： A61K9/5078 , A61K9/5047 , A61K31/4439
摘要： It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the stomach but dissolves in the intestine to release a primary drug product promptly. The object could be achieved by the pharmaceutical composition characterized in that a layer containing a proton pump inhibitor and ethyl cellulose, a layer containing an enteric polymer, and if necessary an intermediate layer composed of one or more layers are formed on a pharmacologically inactive core substance. The intermediate layer is composed of a water-insoluble polymer, a water-soluble polymer, a lubricant and the like.
摘要翻译：旨在提供含有质子泵抑制剂的药物组合物，即使长时间储存也是稳定的。还提供含有对酸敏感的质子泵抑制剂的药物组合物，并且不溶于胃，但溶解于肠中以迅速释放初级药物。该目的可以通过药物组合物来实现，其特征在于，在药理学上不活泼的核心物质上形成含有质子泵抑制剂和乙基纤维素的层，含有肠溶性聚合物的层，如果必要的话，由一层或多层构成的中间层。中间层由水不溶性聚合物，水溶性聚合物，润滑剂等组成。

4. 发明申请

US20090269484A1 Method of measuring coating quantity and method of predicting dissolution behavior 失效
标题翻译：测量涂布量的方法和预测溶出行为的方法
公开(公告)号：US20090269484A1
公开(公告)日：2009-10-29
申请号：US11794763
申请日：2006-02-02
申请人： Makoto Yokoyama , Koji Ukai
发明人： Makoto Yokoyama , Koji Ukai
IPC分类号： B05D1/00
CPC分类号： A61J3/005 , A61K9/282 , A61K9/2846 , A61K9/2866 , G01B11/0625 , G01N21/3563 , G01N21/359 , G01N33/15 , Y10T428/2991 , Y10T428/31504
摘要： Evaluation methods that employ the near infrared spectrum have generally had a low specificity and in particular have encountered difficulty in the evaluation of trace components, and the accurate measurement of coating quantity by methods using the near infrared spectrum has been quite problematic. The quantity of coating applied to a coating target, such as granules or uncoated tablets, is measured based on the absorption or scattering of light in the 800 to 1100 nm wavelength region by an additive coated on the coating target. The use of polyethylene glycol or a long-chain hydrocarbyl-containing compound as the additive is preferred.
摘要翻译：使用近红外光谱的评价方法通常具有低的特异性，特别是在痕量成分的评价中遇到困难，通过使用近红外光谱的方法的涂布量的精确测量已经成问题。基于通过涂覆在涂覆目标上的添加剂在800至1100nm波长区域中的光的吸收或散射来测量施加到涂覆靶材（例如颗粒或未包衣片剂）上的涂层的量。优选使用聚乙二醇或长链烃基化合物作为添加剂。

5. 发明授权

US08252362B2 Method of measuring coating quantity and method of predicting dissolution behavior 失效
标题翻译：测量涂布量的方法和预测溶出行为的方法
公开(公告)号：US08252362B2
公开(公告)日：2012-08-28
申请号：US11794763
申请日：2006-02-02
申请人： Makoto Yokoyama , Koji Ukai
发明人： Makoto Yokoyama , Koji Ukai
IPC分类号： C23C14/54
CPC分类号： A61J3/005 , A61K9/282 , A61K9/2846 , A61K9/2866 , G01B11/0625 , G01N21/3563 , G01N21/359 , G01N33/15 , Y10T428/2991 , Y10T428/31504
摘要： Evaluation methods that employ the near infrared spectrum have generally had a low specificity and in particular have encountered difficulty in the evaluation of trace components, and the accurate measurement of coating quantity by methods using the near infrared spectrum has been quite problematic. The quantity of coating applied to a coating target, such as granules or uncoated tablets, is measured based on the absorption or scattering of light in the 800 to 1100 nm wavelength region by an additive coated on the coating target. The use of polyethylene glycol or a long-chain hydrocarbyl-containing compound as the additive is preferred.
摘要翻译：使用近红外光谱的评价方法通常具有低的特异性，特别是在痕量成分的评价中遇到困难，通过使用近红外光谱的方法的涂布量的精确测量已经成问题。基于通过涂覆在涂覆目标上的添加剂在800至1100nm波长区域中的光的吸收或散射来测量施加到涂覆靶材（例如颗粒或未包衣片剂）上的涂层的量。优选使用聚乙二醇或长链烃基化合物作为添加剂。

6. 发明申请

US20100009003A1 PHARMACEUTICAL PREPARATION TO BE DISPERSED BEFORE ADMINISTRATION 审中-公开
标题翻译：在管理之前要分配的药物制剂
公开(公告)号：US20100009003A1
公开(公告)日：2010-01-14
申请号：US12561776
申请日：2009-09-17
申请人： Koji UKAI , Yasuyuki Asai , Yoshiteru Kato , Takayuki Ohwaki , Shigeru Aoki , Yasuhiro Zaima , Takehiro Yamaguchi
发明人： Koji UKAI , Yasuyuki Asai , Yoshiteru Kato , Takayuki Ohwaki , Shigeru Aoki , Yasuhiro Zaima , Takehiro Yamaguchi
IPC分类号： A61K31/4439 , A61K9/14
CPC分类号： A61K9/0095 , A61K9/5078 , A61K31/717 , A61K45/06
摘要： The present invention provides a pharmaceutical preparation to be dispersed before administration which has an adequate viscosity and a suitable flowability even when dispersed in a small amount of water and can be easily administered through an NG tube is provided. Specifically, the pharmaceutical preparation to be dispersed before administration contains active granules containing a pharmaceutically active substance having an average particle diameter of 5 mm or less and a thickening agent, and can be administered through an NG tube by dispersing in water before administration.
摘要翻译：本发明提供了即使分散在少量的水中也可以容易地通过NG管施用的具有足够的粘度和合适的流动性的在给药前分散的药物制剂。具体地说，给药前待分散的药物制剂含有含有平均粒径为5mm以下的药物活性物质和增稠剂的活性颗粒，并且可以通过NG管通过在给药前在水中分散来给药。

7. 发明申请

US20080145421A1 STABILIZED COMPOSITION 有权
标题翻译：稳定组合物
公开(公告)号：US20080145421A1
公开(公告)日：2008-06-19
申请号：US11937393
申请日：2007-11-08
申请人： Koji Ukai , Norishige Takami
发明人： Koji Ukai , Norishige Takami
IPC分类号： A61K9/48 , A61K31/4184 , A61K31/4439 , A61P1/04 , A61K9/14 , A61K9/30
CPC分类号： A61K31/4184 , A61K9/5047 , A61K9/5078 , A61K31/4439
摘要： It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the stomach but dissolves in the intestine to release a primary drug product promptly. The object could be achieved by the pharmaceutical composition characterized in that a layer containing a proton pump inhibitor and ethyl cellulose, a layer containing an enteric polymer, and if necessary an intermediate layer composed of one or more layers are formed on a pharmacologically inactive core substance. The intermediate layer is composed of a water-insoluble polymer, a water-soluble polymer, a lubricant and the like.
摘要翻译：旨在提供含有质子泵抑制剂的药物组合物，即使长时间储存也是稳定的。还提供含有对酸敏感的质子泵抑制剂的药物组合物，并且不溶于胃，但溶解于肠中以迅速释放初级药物。该目的可以通过药物组合物来实现，其特征在于，在药理学上不活泼的核心物质上形成含有质子泵抑制剂和乙基纤维素的层，含有肠溶性聚合物的层，如果必要的话，由一层或多层构成的中间层。中间层由水不溶性聚合物，水溶性聚合物，润滑剂等组成。

8. 发明申请

US20050042285A1 Stabilized composition comprising a benzimidazole type compound 审中-公开
标题翻译：包含苯并咪唑型化合物的稳定组合物
公开(公告)号：US20050042285A1
公开(公告)日：2005-02-24
申请号：US10938554
申请日：2004-09-13
申请人： Koji Ukai , Masaki Ichikawa , Takashi Kato , Yukiko Sugaya , Yasuyuki Suzuki , Shigeru Aoki , Akira Kato , Masao Kawamura , Satoshi Fujioka
发明人： Koji Ukai , Masaki Ichikawa , Takashi Kato , Yukiko Sugaya , Yasuyuki Suzuki , Shigeru Aoki , Akira Kato , Masao Kawamura , Satoshi Fujioka
IPC分类号： A61K9/20 , A61K31/4184 , A61K31/4439
CPC分类号： A61K31/4439 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K31/4184
摘要： The present invention provides a chemically stable pharmaceutical preparation of a benzimidazole type compound. That is, the present invention relates to a composition comprising at least one substance selected from sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, aminoalkyl methaacrylate copolymer E, arginine aspartate, hydroxypropyl cellulose and crospovidone incorporated into a benzimidazole type compound or an alkali metal salt thereof.
摘要翻译：本发明提供苯并咪唑型化合物的化学稳定的药物制剂。也就是说，本发明涉及包含至少一种选自碳酸钠，碳酸钾，氢氧化钠，氢氧化钾，氨基烷基甲基丙烯酸酯共聚物E，精氨酸天冬氨酸盐，羟丙基纤维素和交聚维酮中的物质的组合物，其结合到苯并咪唑型化合物或碱金属盐。

9. 发明授权

US07220762B1 Methods for stabilizing benzimidazole compounds 有权
标题翻译：稳定苯并咪唑化合物的方法
公开(公告)号：US07220762B1
公开(公告)日：2007-05-22
申请号：US10110679
申请日：2000-10-19
申请人： Koji Ukai , Satoshi Fujioka , Mitsuru Mizuno , Makoto Yokoyama , Shigeru Aoki , Masao Kawamura
发明人： Koji Ukai , Satoshi Fujioka , Mitsuru Mizuno , Makoto Yokoyama , Shigeru Aoki , Masao Kawamura
IPC分类号： A61K31/4184 , A61K31/4439 , C07D401/12
CPC分类号： A61K9/2886 , A61K9/2009 , A61K9/2027 , A61K31/4439 , A61K47/02 , A61K47/32 , C07D401/12
摘要： The present invention provides a method for stabilizing an oral solid formulation containing a benzimidazole-based compound or a physiologically acceptable salt thereof. That is, it provides a method for stabilizing a benzimidazole-based compound or a physiologically acceptable salt thereof, comprising incorporating 1) a crospovidone or a crospovidone and 2) sodium hydroxide and/or potassium hydroxide to a benzimidazole-based compound or a physiologically acceptable salt thereof.
摘要翻译：本发明提供一种稳定含有苯并咪唑类化合物或其生理上可接受的盐的口服固体制剂的方法。也就是说，它提供了一种稳定基于苯并咪唑的化合物或其生理上可接受的盐的方法，包括将1）交聚维酮或交联聚维酮和2）氢氧化钠和/或氢氧化钾加入苯并咪唑基化合物或生理上可接受的盐的盐。

10. 发明申请

US20060165793A1 Pharmaceutical preparation to be dispersed before administration 审中-公开
标题翻译：给药前待分散的药物制剂
公开(公告)号：US20060165793A1
公开(公告)日：2006-07-27
申请号：US10564402
申请日：2004-08-04
申请人： Koji Ukai
发明人： Koji Ukai
IPC分类号： A61K31/717 , A61K9/26
CPC分类号： A61K9/0095 , A61K9/5078 , A61K31/717 , A61K45/06
摘要： The present invention provides a pharmaceutical preparation to be dispersed before administration which has an adequate viscosity and a suitable flowability even when dispersed in a small amount of water and can be easily administered through an NG tube is provided. Specifically, the pharmaceutical preparation to be dispersed before administration contains active granules containing a pharmaceutically active substance having an average particle diameter of 5 mm or less and a thickening agent, and can be administered through an NG tube by dispersing in water before administration.
摘要翻译：本发明提供了即使分散在少量的水中也可以容易地通过NG管施用的具有足够的粘度和合适的流动性的在给药前分散的药物制剂。具体地说，给药前待分散的药物制剂含有含有平均粒径为5mm以下的药物活性物质和增稠剂的活性颗粒，并且可以通过NG管通过在给药前在水中分散来给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式